AstraZeneca announced today that its anti-COVID-19 antibody drug was 83% effective in reducing the risk of developing a symptomatic disease over a six-month period, according to a follow-up test.
This treatment, given in injectable form and called AZD7442 or Evusheld, had previously been shown to provide 77% protection against symptomatic disease after three months, in a previous display of the results of the PROVENT final stage test in August.
The British-Swedish company also reported that a separate trial, conducted in patients with mild to moderate COVID-19, showed that a higher dose of AZD7442 reduced the risk of worsening symptoms by 88% when given within three days of the onset of symptoms. .
“These new data add to the growing body of evidence supporting AZD7442’s ability to make a significant difference in the prevention and treatment of COVID-19,” said Mene Pangalos, the company’s executive vice president.
Source: AMPE
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
